Expert Discusses Ongoing Advances With Immunotherapy in CRC – OncLive
OncLive |
Expert Discusses Ongoing Advances With Immunotherapy in CRC
OncLive An emerging area of research is attempting to have the remaining 96% of patients with CRC respond to immunotherapy. An ongoing phase III study is investigating that question by combining the MEK inhibitor cobimetinib (Cotellic) with the PD-L1 inhibitor … |
